Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Tennessee: - Memorial Hospital — Chattanooga, Tennessee
- Baptist Memorial Hospital and Cancer Center-Collierville — Collierville, Tennessee
- Pulmonary Medicine Center of Chattanooga-Hixson — Hixson, Tennessee
- Baptist Memorial Hospital and Cancer Center-Memphis — Memphis, Tennessee
- Baptist Memorial Hospital for Women — Memphis, Tennessee
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Tennessee: - Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Tennessee: - Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harborin…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Tennessee: - SCRI - TriStar Medical Group Children's Specialists — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in Tennessee: - Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Tennessee: - Tennessee Oncology — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT06528691
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …
Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Tennessee: - Sarah Cannon Research Institute - Pharmacy — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
- TriStar Bone Marrow Transplant — Nashville, Tennessee
- TriStar Centennial Medical Center - Cell Processing Lab — Nashville, Tennessee
- TriStar Centennial Medical center — Nashville, Tennessee
Phase 1 Recruiting Network
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…
Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
EARLY Phase 1 Recruiting Academic/Other
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Sponsor: Vanderbilt-Ingram Cancer Center
NCT ID: NCT05996432
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
EARLY Phase 1 Recruiting Academic/Other
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patien…
Sponsor: Eben Rosenthal
NCT ID: NCT07210632
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Recruiting Industry
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT04427384
Sites in Tennessee: - CHI Memorial Hospital, CommonSpirit — Chattanooga, Tennessee
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Tennessee: - Baptist (BHMCC) — Memphis, Tennessee
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
NA Recruiting Academic/Other
Low-grade gliomas (LGGs) are the most common brain tumors in children, and a subset of these tumors are treated definitively with focal radiation therapy (RT). These patients often survive for many years after receiving RT and experience l…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04065776
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Recruiting Academic/Other
The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be con…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT07085325
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee